Data Provenance
How This Data Was Built
Every record in this database started with a patient who raised their hand.
Not a claim. Not a model. Not a purchased list. A real person who saw a condition-specific unbranded ad, clicked, landed on a condition-specific page, and completed a form. The patient self-identified their condition. They expressed interest in treatment. Many of them went on to receive supply.
That is the conversion event that makes this data irreplaceable — a completed condition-specific landing page from a real patient with a real condition. The entire database starts at that moment. T1 patients converted to confirmed supply. T2 patients qualified but hit an access barrier. T3 is the full post-conversion universe of everyone who raised their hand.
To build this from scratch today, a pharma brand or data company would need to run tens of millions in condition-specific paid media across years of campaigns, deduplicate at scale, and maintain consent compliance over time. At typical CPL rates for condition-specific healthcare audiences, the replacement cost runs into hundreds of millions of dollars. It does not exist on any data marketplace because nobody else built a healthcare patient acquisition business this way over this period of time.
You get exclusive access to a first-party data layer built through a decade of direct-to-consumer healthcare marketing investment — under a 20-year license, with no platform overhead. Better targeting. Higher match rates. Predictable ROI.
1,008,348 fill records · avg 7.2 fills per patient
Competitive Moat
Why this dataset
cannot be replicated.
Summit's first-party data layer was built through proven direct-to-consumer methodology — under exclusive 20-year license through 2046, with no platform overhead. Better targeting precision, higher match rates, predictable campaign ROI. Direct data advantage.
Why Summit
Confirmed patient data your competitors literally cannot access. 20-year exclusive license through 2046.
Summit's exclusive data licensing partnership gives you first-party, deterministic patient audience data that simply doesn't exist anywhere else.
The Summit Difference
From fragmented signals to verified de-identified patient journeys
Modeled, Third-Party Guesswork
Audience segments built on probabilistic models, purchased lists, and look-alike approximations. High overlap with competitor buys. Low match rates. Campaigns targeting people who don't actually have the condition.
Verified Four-Tier Patient Journeys
Four distinct tiers of de-identified, first-party patient data. Every record confirmed through real patient interaction — from Rx delivery back to initial intent signal. Identity-graph compatible delivery.
Data Architecture
Four tiers. Increasing depth at each level.
The dataset spans the full acquisition and customer funnel, plus an adjacent prescriber layer. Volume is largest at the top; data richness increases with each successive tier.
Tx-Verified Supply
Active Customers · Deepest SignalDx-Qualified Near-Miss
Onboarded · Mid FunnelCondition-Confirmed Intent Panel
Verified Intent · Top of FunnelHCP Intelligence
Prescriber Intel · Adjacent LayerConfirmed Comorbidity
Multi-Condition · Dual-IndicationGLP-1 Fulfillment
Summit-Operated · CumulativeTIER 3 · NEW PATIENT ACQUISITION
Tier 3 — The 15.3M New Patient Acquisition Asset
T3 is the new patient acquisition asset for your brand. These are not newly diagnosed patients — they are diagnosed, in-market, and actively shopping for a new way to manage their condition: mail-order Rx, supply delivery, or insurance coverage. They self-identified by completing a form or calling in on an unbranded category-level offer for their specific condition. For a pharma brand or health plan, this is the most acquirable population in healthcare data — already engaged with healthcare, already signaling they want a change, and uncommitted to a specific drug or supplier at the point of capture. T1 is what happened when T3 patients converted to confirmed supply. T2 is what happened when they qualified but hit an access barrier. T3 itself is 15.3M in-market patients sitting at the top of that funnel.
INBOUND CLICK-TO-CALL — THE PREMIUM INTENT LAYER
~2.15M records of patients who saw a condition-specific unbranded ad and picked up the phone. Higher intent than any form fill — the patient initiated contact. This sub-segment commands a CPM premium and is the highest-converting layer of T3.
FORM COMPLETIONS — THE SCALE LAYER
~13.1M records of patients who completed a condition-specific supply form. Each record carries the condition, the Rx interest, and the activation fields a DSP needs. CPM-activatable at scale across The Trade Desk, DV360, Meta, and CTV.
CATEGORY-LEVEL CAPTURE
Unbranded mail-order Rx, supply delivery, and Medicare / insurance campaigns. No specific drug. No brand loyalty captured at the point of inquiry. Patients are open to any acquirer.
CONDITION-CONFIRMED
The patient stated the condition themselves at form submission or during the inbound call. Nothing inferred, modeled, or scraped from behavior.
DIAGNOSED & IN-MARKET
Not newly diagnosed. Already managing their condition and actively shopping for a new supplier, delivery channel, or coverage plan. The most acquirable patient population in healthcare data.
DEDUPLICATED AT THE INTENT EVENT LEVEL
15.3M condition-confirmed inquiries from 12.17M unique patients across 5 conditions. Avg ~1.3 intent events per patient — a repeat-engagement signal stronger than single-touch lead databases.
WHY T1 AND T2 PROVE T3 WORKS
Every T1 patient entered through T3. 140,216 T3 records converted to confirmed T1 supply. 218,071 converted to T2 qualified-but-near-miss. 358,287 total T3 records with documented downstream tier confirmation. These are the conversion metrics of the funnel — T3 is the top, T1 is the bottom. When a pharma brand seeds a lookalike from T3 and measures script lift, T1 and T2 confirmed match rates are the proof it worked.
GLP-1 Market Opportunity
GLP-1 New Patient Acquisition — Three Activation Layers
Summit's GLP-1 audience opportunity operates across three distinct layers. Each serves a different campaign objective.
Layer 1 — New Patient Acquisition at Scale (T3)
~15.3M Intent Panel records — condition-confirmed hand-raisers who self-identified a diabetes or related condition and completed a condition-specific landing page. As of July 1, 2026 these patients are in the Medicare GLP-1 coverage window. This is the new patient acquisition audience — confirmed condition intent, CPM-activatable at scale.
Summit's Intent Panel is the largest CPM-activatable confirmed-intent GLP-1 new patient acquisition audience available in the healthcare data market.
Layer 2 — Confirmed Supply Patients (T1)
140,216 confirmed T1 diabetics with longitudinal supply history and prescriber linkage. Average 7.2 documented fill records per patient. Highest-value GLP-1 activation audience — confirmed diagnosis, confirmed prescriber, documented treatment history dating back to 2016.
L3 — Summit-Operated GLP-1 Patient Layer
19,470 unique GLP-1 patients across all 50 US states. 98.9% phone-hash coverage (18,053 unique). 79% female / 21% male. Summit operates the fulfillment pipeline directly as the HIPAA covered entity in each shipping transaction. Under separate HIPAA-safe handling from the de-identified hashed tiers — suitable for operational data partnerships, adherence campaigns, and RWE measurement programs.
Medicare GLP-1 Bridge effective July 1, 2026. Wegovy, Zepbound, and Foundayo available at $50/month to Medicare Part D beneficiaries with qualifying conditions including Type 2 Diabetes, cardiovascular disease, and obstructive sleep apnea. Summit's full Intent Panel of 15.3M records is now directly in the GLP-1 coverage window.
The Summit Advantage
The toolkit that makes your healthcare campaigns perform
Reach de-identified patients who actually get treatment
De-identified Tier 1 audience records include only patients with a confirmed doctor's prescription AND completed medical fulfillment. The highest-intent, lowest-waste de-identified segment in healthcare advertising.
Reporting your compliance team can trust
Full HIPAA Safe Harbor de-identification, documented data lineage, and complete audit trails. All data is de-identified per 45 CFR §164.514(b). Not just advertiser-safe — actually compliant. Legal reviews in days, not months.
Data Quality
The data quality your healthcare campaigns deserve
Healthcare campaigns are only as good as the patient data behind them. Summit's four-tier approach means every audience is built on exclusive, first-party data from real patient journeys — verified condition signals, not probabilistic modeling, not self-reported surveys.
Data Infrastructure
The Pipeline Behind the Data
Continuous intake across all five campaign categories
The only documented hand-raised-to-confirmed-supply conversion path in commercial healthcare data.
Activation Surface
What the Data Can Do
Summit's tiers serve different pharma buyer personas — DTC, medical affairs, access programs, measurement, HCP marketing. The same data layers map to different use cases depending on which team is buying. Eight applications cover the full pharma activation surface.
Acquisition
New Patient Acquisition
First-party post-conversion patient seed for prospecting campaigns. Verified condition + in-market behavior — not modeled.
Modeling
Lookalike Modeling
Seed quality determines model quality. Summit's observed, post-conversion patients produce dramatically better lookalikes than 3rd-party or claims-derived seeds.
AI Input
AI / Audience Training
Verified condition + intent + identity is premium training input for proprietary pharma AI and predictive models.
Optimization
Retargeting & Suppression
Suppress T3 hand-raisers from impression campaigns to redeploy budget on net-new audiences. Retarget T1/T2 for adherence and re-engagement.
Access Programs
Access Program Targeting
Patients clinically qualified but blocked by insurance, authorization, or documentation — exactly the population pharma access programs are built for.
Adherence
Adherence, Persistence & Retention
Multi-year supply behavior with patient-level fill cadence on file. Target at predicted refill or abandonment moments.
HCP Activation
HCP Targeting & Prescriber Activation
166,464 prescriber NPIs linked to confirmed patient volume — warm prescribers, not cold specialty codes.
Attribution
Closed-Loop Outcomes Attribution
Match Summit-seeded campaigns to downstream supply fulfillment. 140,216 T3→T1 confirmed converts demonstrate end-to-end funnel velocity.
ONE DATASET. EIGHT USE CASES.
The same Summit identity infrastructure that supports new patient acquisition for one pharma client supports adherence measurement for another and access program targeting for a third — same patients, different teams, different campaigns. Buyers activate at the use case that matches their team's KPIs.
Confirmed Comorbidity Cohorts
The strongest signal in healthcare data is the same patient across multiple condition pathways.
Summit's hashed-phone identity layer surfaces 34,721 such individuals across T1 + T2, and an additional 43,862 in the Medicare Advantage panel — patients with confirmed supply or completed intake on each condition pathway.
T3 Universe — 5-Condition Comorbidity Matrix
All overlaps verified at phone-hash level — real patients on multiple condition pathways, not modeled prevalence.
Tier 1 + Tier 2 Phone Universe — 351,508 Unique Identities
Medicare Advantage Cross-Confirmation — 43,862
Apex Cross-Domain Audience
The intersection of multiple condition pathways with confirmed sale or handoff. Premium audiences for GLP-1 Bridge campaigns, specialty pharma, and Medicare-aligned therapy.